We estimated the association between bacillus Calmette-Guérin (BCG) vaccination and childhood asthma in a birth cohort using administrative databases, and we determined the impact of adjusting for potential confounders collected from a subset of the cohort members. Data were collected in 2 waves: 1) Administrative data for 76,623 individuals (stage 1) was gathered from the Quebec Birth Cohort on Immunity and Health (1974-1994), including BCG vaccination status, perinatal and sociodemographic characteristics, and use of health services for asthma; and 2) selfreported asthma risk factors were collected in 2012 by telephone interviews with 1,643 participants (stage 2) using a balanced 2-stage sampling design. We estimated odds ratios and 95% confidence intervals for asthma using logistic regression and correcting for the known sampling fractions from stage 1 to stage 2, overall and sex-stratified. In total, 35,612 (46.5%) individuals were BCG vaccinated, and 5,870 (7.7%) had asthma. The final odds ratio, integrating results from both stages of sampling, was 0.95 (95% confidence interval: 0.87, 1.04). Results did not differ according to sex (P for interaction = 0.327). To our knowledge, this is the largest study ever conducted on this topic, and using the best possible comprehensive adjustment for confounders, we found no association between BCG vaccination and asthma.
Bacillus Calmette-Guérin (BCG), the nonpathogenic strain of live attenuated Mycobacterium bovis, was first used in the 1920s to vaccinate humans against tuberculosis. This vaccine has important nonspecific effects beyond tuberculosis protection (1) (2) (3) . Unlike most other vaccines, which stimulate Th2 lymphocytes and antibody production, the BCG vaccine induces Th1 lymphocytes and cell-mediated immunity (4) (5) (6) . This drives the immune response towards a Th1 response rather than the Th2 response that is prototypical of atopic disorders (7) , suggesting that BCG vaccination could contribute to asthma prevention. Its effect may be especially relevant when administered in infancy, an important time window for maturation of the immune system (8) .
The modulation of immune maturation and function resulting from BCG vaccination and its role in the development of inflammatory diseases has generated considerable interest (9) . Systematic reviews and meta-analyses of epidemiologic studies on the relationship between BCG vaccination and childhood asthma, in particular, showed conflicting results of no association (10, 11) or a protective association (12) . A lower asthma risk was suggested in another meta-analysis, but a sensitivity analysis indicated that it was due to publication bias (13) . Discrepancies in findings across original individual studies may be explained by methodological heterogeneity, possible misclassification of exposure and outcome measures, lack of power, and lack of comprehensive adjustment for confounders.
Childhood asthma poses a challenge for the health-care system and causes an economic burden at the individual and societal levels (14) (15) (16) . Investigating an agent such as BCG vaccination could provide clues to the immunological mechanisms and, if its role in asthma prevention could be established, could lead to preventive actions.
Between 1949 and 1974, a province-wide BCG vaccination program offered free but voluntary vaccination to neonates and school-age children in Quebec, Canada. All BCG vaccinations carried out in the province were recorded in a central registry, which was recently computerized (17) . The ability to successfully link it with administrative databases provided us with a unique opportunity to assemble a large, population-based birth cohort to assess the association between BCG vaccination and asthma.
In this context, the Quebec Birth Cohort on Immunity and Health (QBCIH) was set up with 2 main aims: 1) to estimate, at the population level, the relationship between BCG vaccination and asthma occurrence, while adjusting for potential confounders available in administrative demographic and medical databases; and 2) to evaluate the impact of further adjustment for other potential confounders, unavailable in administrative databases, on the observed measures of association by collecting such information from a subset of the study population.
METHODS

QBCIH study design and population
A detailed description of the QBCIH methodology has been published previously (18, 19) . Briefly, this retrospective, population-based birth cohort was assembled through the linkage of several administrative demographic and medical databases: the provincial Birth Registry, the provincial Healthcare Registration File for 2010 (universal public health system), and the Quebec BCG Vaccination Registry. Figure 1 presents details of the cohort setup, sampling process, and participation rates. The cohort included 81,496 members, representing 90.5% of those who were eligible: all children born at ≥32 weeks of gestation in the province of Quebec, Canada, in 1974. They were followed for asthma occurrence until the age of 20 years, in 1994. The present analytical sample (referred to as stage 1) included eligible children (n = 76,623) who had valid information on both the exposure and outcome of interest. We used a 2-stage sampling strategy with a balanced design (20) to collect information that was lacking in administrative databases. First described in the 1980s (21, 22) , 2-stage sampling consists of obtaining data on potential confounders from a subset of individuals, and combining it with exposure and outcome information documented for all study participants in order to estimate an adjusted measure of association and confidence interval (20) . Several sampling approaches exist, but the balanced design almost always maximizes cost-efficiency and precision (22, 23) . Therefore, a subset of cohort members was randomly selected among 4 strata defined by BCG vaccination and asthma status, oversampling from the smallest cells of the 2 × 2 table (individuals with asthma, with or without BCG vaccination). Detailed information on a wide range of covariates covering the period from birth to age 20 years was obtained by interviewing 1,643 participants (referred to as the stage-2 sample). We recently reported on the validity of the stage-2 sample, demonstrating stratum-specific representativeness of stage-2 participants in terms of sociodemographic characteristics and healthcare utilization relative to the stage-1 sample (19).
The current study was approved by the Commission d'accès à l'information du Québec and the research ethics committees of INRS, Fonds de recherche du Québec-Santé, Régie de l'assurance maladie du Québec, and Statistics Quebec (Institut de la statistique du Québec). A confidentiality agreement protecting the privacy of research subjects was signed by all members of the research team.
Data acquisition and collection
Two different sources of data were used: retrospective follow-up of all cohort members through administrative databases and, for a subset, self-reported information. Baseline perinatal and sociodemographic data were available at birth (1974) , and data on BCG vaccination (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) , medical services (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) , and hospitalization (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) were acquired according to the available time frame of coverage for each database. Stage-2 participants completed a computer-assisted telephone interview administered by trained interviewers (between April 26, 2012, and July 7, 2012), eliciting information on predictors of asthma development.
Exposure and outcome variables
Two exposure measures were used: BCG vaccination (no, yes) and age at BCG vaccination (unvaccinated, <1 year of age, ≥1 year of age), as documented in the registry. The centralized registry was an integral part of the BCG vaccination program funded and headed by the provincial Health Ministry from 1949 to 1974 (24) (25) (26) . The vaccine was offered to children and adults considered to be at higher risk of infection, and, more systematically, to newborns (within a month of birth) and schoolchildren (25) . Before vaccination, all except newborns undertook an intradermal test to determine reactivity, and those with negative results were vaccinated. Medical institutions and affiliated mobile vaccination teams were given clear guidelines from the Health Ministry to send intradermal test and vaccination records to the centralized registry, which was recently computerized and has been shown to be highly complete and accurate (17) . Cohort members who were not documented in the registry as having been vaccinated were considered to be unvaccinated.
The outcome of interest was defined using the number of asthma-related health-care encounters retrieved from administrative health databases using the entire available follow-up for each individual. Asthma was defined as having had at least 2 asthma-related medical services or at least 1 asthmarelated hospitalization (International Classification of Diseases, Ninth Revision, code 493). The validity of defining asthma cases based on Canadian administrative health data has previously been demonstrated (27, 28) .
Covariates
Data on potential confounding variables for all individuals were extracted from the provincial Birth Registry (29) and Healthcare Registration File (30, 31) . From the latter, residential postal codes in 1991 were used to determine 1) area of residence based on the second character of the postal code ("rural" denoted by a 0 or "urban" denoted by values 1-9) (32), and 2) family income estimated by median household income from the 1991 Canadian census, using the first 3 characters of the postal codes. Information collected by interview included asthma risk factors such as familial history of asthma and allergic diseases, personal history of childhood infectious diseases, immunizations, exposure to tobacco smoke in childhood, pet ownership, breastfeeding, daycare attendance, parental education, and occupation.
Statistical analyses
For the first objective, 2 logistic regression models, estimating odds ratios and 95% confidence intervals, were fitted using data from the stage-1 sample (n = 76,623) to assess the association between each exposure indicator (BCG vaccination, age at BCG vaccination) and the occurrence of asthma. The reference group consisted of unvaccinated individuals. The stage-1 sample comprised 94% of the Quebec Birth Cohort on Immunity and Health. Undetermined asthma status includes individuals who had only 1 asthma-related medical visit during 1983-1994. A subset of cohort members was randomly selected for stage 2 across 4 strata defined by BCG vaccination and asthma status. A valid telephone number was found for 70% of the individuals present in the Healthcare Registration File (no differences according to stratum). Among those, the participation rate was 56%, with stratum-specific estimates ranging from 54% to 58%. The sampling fractions were 0.1734 for individuals who were bacillus Calmette-Guérin-positive (BCG+) and asthma-positive (asthma+), 0.0135 for those who were BCG+ and asthma-negative (asthma-), 0.1167 for those who were BCG-negative (BCG-) and asthma+, and 0.0097 for those who were BCG-and asthma-.
Initially, Cox proportional hazards regression models were fitted. Time to event was considered to be from 1983 (no medical information was available for 1974-1982) until the first occurrence of an asthma-related health-care encounter, the end of follow-up (1994), or the end of health coverage, whichever came first. Risk estimates were comparable to those derived from fitting logistic models, and we used the latter because they are better suited to analytical methods for 2-stage sampling strategies (20) . Regression models included a priori potential confounding variables available in administrative databases: sex, birth weight for gestational age (very small, small, appropriate, or large for gestational age) according to a Canadian sex-specific reference (33), number of older siblings (0, 1, >1), maternal age at childbirth (<35 years, ≥35 years), paternal age at childbirth (<40 years, ≥40 years), maternal and paternal birthplace (in Quebec, outside Quebec), area of residence in 1991 (rural, urban), and census-based annual family income (in Canadian dollars by quartile: ≤35,333; 35,334-40,667; 40,668-47,289; and ≥47,290). Missing data for covariates were treated as a separate category.
For the second objective, the adjusted association in the stage-2 sample (n = 1,643) was estimated using multiple logistic regression. An iterative process of covariate selection was used (34) (35) (36) , considering an initial list of potential asthma risk factors and factors associated with BCG vaccination in this population (e.g., parental birthplace, urban or rural residence) (18) . Variables from administrative databases and interviews with a univariate P value of <0.25 were included in the initial model. Covariates were retained if they remained significant at the 0.1 level or if they resulted in a >10% change in the BCGasthma parameter estimates when removed. At the end of the modeling process, variables not initially selected for the multivariable analysis were reevaluated using the same criteria. Final estimates of association were obtained by correcting the fully adjusted odds ratios and 95% confidence intervals estimated from the stage-2 sample with the known sampling fractions (from stage 1 to stage 2; see Figure 1 ), as previously described (20) . The known sampling fractions allow correction for the "selection bias" introduced by oversampling individuals belonging to strata with smaller counts in the original sample table (20, 37) . The validity of this approach relies on representativeness of the stage-2 sample, which we recently demonstrated (19) . Analyses were conducted overall and by sex.
We compared results from complete-case analyses (deletion of observations with missing values) with our main results. We also conducted sensitivity analyses excluding individuals with interruptions in provincial health insurance coverage between 1983 and 1994, to ascertain whether a lack of health coverage (i.e., loss to follow-up) had an effect on observed point estimates. All analyses were carried out using SAS Enterprise Guide, version 5.1 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Population characteristics
In the stage-1 sample, 32,900 (42.9%) individuals received the vaccine within their first year of life, whereas 2,712 (3.5%) were vaccinated later. The prevalence of asthma was 7.7% overall-6.8% among men and 8.5% among women. Characteristics of the stage-1 sample, as documented in administrative databases, are presented according to asthma status along with crude odds ratios and 95% confidence intervals (Table 1) . Similarly, Table 2 displays self-reported characteristics among participants of the stage-2 sample according to asthma status and crude associations with asthma. By design, half (50.6%) of these participants had asthma.
Selection of adjustment variables
For the second objective, potential candidates retained for the multivariable model based on univariate associations included variables acquired from administrative databases (sex, parental age, parental place of birth, number of older siblings, area of residence, family income) and self-reported variables (breastfeeding, daycare attendance, parental smoking during pregnancy and before the child's 10th birthday, family (mother, father, siblings) history of asthma and of allergic diseases (eczema, rhinitis, or food allergy), personal history of whooping cough). The final, most parsimonious model included census-based family income, area of residence, breastfeeding, family history of asthma (maternal, paternal, and sibling), and maternal and paternal history of allergic diseases.
Association between BCG vaccination and childhood asthma Table 3 presents crude and adjusted estimates of the association between each exposure indicator and asthma occurrence in the stage-1 sample as well as final estimates-adjusted for variables from administrative databases and interviews, and corrected for sampling fractions-along with corresponding 95% confidence intervals. In the stage-1 sample, a slightly lower asthma risk was observed in vaccinated compared with unvaccinated individuals after adjustment for variables avail- Results stratified by sex are shown in Table 4 . Estimates from the stage-1 sample did not differ according to sex, and they suggested a protective association between BCG vaccination and asthma risk. In the final estimates, there was no difference by sex (P for interaction = 0.327). For BCG vaccination, the final odds ratio was 0.87 (95% CI: 0.75, 1.00) in men and 1.03 (95% CI: 0.92, 1.16) in women. Final estimates according to age at BCG vaccination were highly similar to these and also did not differ by sex (P for interaction = 0.188 Abbreviations: CI, confidence interval; OR, odds ratio. a Asthma was defined as having at least 2 asthma-related medical services or at least 1 asthma-related hospitalization. b Odds ratios were estimated for categories representing missing values but are not presented here. c Determined using the second character of cohort members' residential postal codes (data from the Régie de l'assurance maladie du Québec, 1991; 0: rural, and not 0: urban).
d In Canadian dollars, estimated by "median family income" from the 1991 Canadian census using the first 3 characters of cohort members' residential postal code. for vaccination during the first year of life and 0.163 for vaccination later in life). Risk estimates from complete-case analyses, based on 67,637 stage-1 and 1,600 stage-2 sample participants, were highly similar to those reported in Table 3 (data not shown). Results did not differ by sex (P for interaction was 0.637 for BCG vaccination, 0.419 for vaccination during the first year of life, and 0.129 for vaccination later in life). We then restricted the analysis to individuals who had uninterrupted medical coverage over the entire followup (i.e., no loss to follow-up: n = 73,806 (96.3%) in stage-1 sample and n = 1,608 (97.9%) in stage-2 sample). We found that results did not differ from those presented in Table 3 . There were also no differences according to sex (P for interaction was 0.249 for BCG vaccination, 0.148 for vaccination during the first year of life, and 0.241 for vaccination later in life). The proportion of individuals who had interruptions in medical coverage during follow-up was 5.0% among unvaccinated individuals and 2.1% among vaccinated individuals. The median number of days of coverage interruption (either temporary or from loss to follow-up) was 1,431 and 974, respectively.
DISCUSSION
Epidemiologic evidence concerning the association between BCG vaccination and childhood asthma is equivocal. To our knowledge, this study is the largest ever to address the association between BCG vaccination and the development of asthma at the population level. It combined the statistical power of large population numbers and the ability to adjust for potential confounders with information gathered among a subsample of the initial study population. Overall, the final risk estimates pointed towards an absence of association, irrespective of age at BCG vaccination.
Our results provide support for earlier meta-analyses (10, 11, 13). Balicer et al. (10) reported a pooled odds ratio of 0.98 (95% CI: 0.88, 1.08), indicating the absence of an association between BCG vaccination and the occurrence of asthma in childhood. Arnoldussen et al. (13) observed a pooled odds ratio of 0.73 (95% CI: 0.56, 0.95) based on 12 studies but with considerable heterogeneity; they concluded that publication bias could explain the protective association. In an update of their metaanalysis, adding 4 studies, they reported a pooled odds ratio of 0.95 (95% CI: 0.89, 1.00) (11) . In contrast, we estimated a pooled odds ratio of 0.86 (95% CI: 0.79, 0.93) in a meta-analysis based on 16 studies (12) .
Because all study participants were born on the last active year (1974) of the BCG vaccination program in Quebec, the vast majority of individuals received the vaccine in their first year of life. This enabled studying BCG vaccination during a critical time period in early life, which could influence immune system maturation (8) . Combining results from 6 epidemiologic studies-5 of which suggested a protective association between neonatal BCG vaccination and the occurrence of childhood The models adjusted for sex, birth weight for gestational age, census-based family income, area of residence, number of older siblings, parental age, and parental place of birth. Missing values for covariates were treated as a separate category. The models adjusted for census-based family income, area of residence, breastfeeding, maternal history of asthma, paternal history of asthma, siblings' history of asthma, maternal history of allergic diseases, and paternal history of allergic diseases. Missing values for covariates were treated as a separate category.
asthma (38-42) and 1 in which there was no association (43)-we previously reported a possible protective role of BCG vaccination against asthma among children vaccinated within their first year of life (pooled OR = 0.86, 95% CI: 0.79, 0.94) (12) . To our knowledge, the single randomized controlled study on primary prevention of childhood asthma in high-risk infants showed no difference in asthma prevalence at 18 months of follow-up between the BCG-and placeboadministered groups (44) . However, a longer period of follow-up, if available, would provide stronger evidence on the role of early BCG vaccination in the development of asthma.
Strengths and limitations
The QBCIH has a number of methodological strengths, including its 1) high population-based coverage and representativeness, with a large sample size exceeding that of previous meta-analyses (11, 12) ; 2) lengthy follow-up; 3) valid 2-stage sample (no indication of a lack of representativeness of stage-2 participants, when compared with the study population from which they were identified or with nonrespondents) (19); and 4) efficiency by way of a 2-stage sampling design to obtain additional information on a wide array of potential confounders unavailable in administrative databases. Interestingly, if we were to rely on models that only adjusted for potential confounders retrieved from administrative databases, we would have concluded from the analyses of the stage-1 sample that there was a significant protective association between BCG vaccination and childhood asthma. This, however, would have disregarded a limitation of administrative datasets established for purposes other than etiologic research. Using questionnaire-elicited information allowed us to further adjust the observed estimates of association, which represented a major improvement over the sole use of administrative data. Although the same argument would not necessarily apply to other health outcomes for which little is known about risk factors, this is true for asthma, a disease that is heterogeneous and multifactorial in nature.
In addition, recall bias in measuring the exposure and outcome of interest, and resulting misclassification, was minimized because these variables were retrieved from administrative and medical databases in which data are routinely and prospectively recorded. Self-report of BCG vaccination status has been shown to have low validity and thus more likely to result in substantial misclassification than use of medical records (45, 46) .
A number of limitations must be acknowledged. One relates to the unavailability of prescription drug claims data, which might have strengthened the algorithm for defining asthma. In the study period, public health coverage of pharmaceutical services, and thus the prescription drug claims database, were restricted to individuals over 65 years of age, welfare recipients, and their children. Another limitation is that we could not differentiate between extrinsic (allergic) and intrinsic (nonallergic) asthma, and thus misclassification of asthma cannot be ruled out. Moreover, lack of coverage of health databases for the period 1974-1982 precluded identifying health-care encounters for asthma that occurred from ages 0-8 years, unless individuals had other asthma-related medical visits or hospitalizations during ages 9-20 years. We cannot assume that all cases of asthma developing in this cohort were identified. Lack of coverage between 1974 and 1982 might have resulted in missing sporadic cases of asthma or wheezing that resolved by age 9. These mildest asthma cases would be included in the nondiseased group, as would, correctly, those who presented with only transient wheezing. Although wheezing is common in the first years of life, only a fraction of these children go on to develop childhood asthma, underlying the importance of considering asthma persistence during later childhood for defining asthma status (47) (48) (49) . Natural history studies of asthma suggest that individuals with persistent asthma symptoms in childhood will most likely continue to have asthma later in life (50, 51) . In fact, 60% of Canadian children with asthma visited their physicians at least 3 times in the previous year (14) . The follow-up from ages 9-20 years would have therefore allowed identification of the most persistent cases as well as new asthma cases.
It is worth noting that a small proportion of children were vaccinated after their first year of life and that this affected statistical power for estimating odd ratios in this subgroup in both the stage-1 and stage-2 samples.
Finally, we cannot rule out misclassification of vaccination status, but there exists no gold standard with which we can compare the registry data. In the only study comparing the registry information with childhood vaccination booklets, overall agreement was 78% (κ = 0.56) among 369 individuals (52) . Discrepancies may have resulted from vaccinations not being entered either in the registry or in the vaccination booklet, and so these results do not indicate which source was incomplete. If present, we would expect misclassification to be nondifferential with respect to asthma status, which would have generated odds ratios closer to the null value and might thus have obscured a true association.
Conclusion
The initially observed reduced risk of asthma among BCG-vaccinated individuals was no longer present when we adjusted for several important potential confounders unavailable from administrative databases, highlighting the benefit of a 2-stage sampling. In conclusion, using the best possible comprehensive adjustment for confounders, overall results suggested no association between BCG vaccination and the development of childhood asthma.
